Adding liposomal doxorubicin enhances the abscopal effect induced by radiation/αPD1 therapy depending on tumor cell mitochondrial DNA and cGAS/STING.
Combined Modality Therapy
Immunotherapy
Programmed Cell Death 1 Receptor
Radioimmunotherapy
Radiotherapy
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
accepted:
21
07
2023
medline:
31
8
2023
pubmed:
29
8
2023
entrez:
28
8
2023
Statut:
ppublish
Résumé
Localized radiotherapy (RT) can cause a T cell-mediated abscopal effect on non-irradiated tumor lesions, especially in combination with immune checkpoint blockade. However, this effect is still clinically rare and improvements are highly desirable. We investigated whether triple combination with a low dose of clinically approved liposomal doxorubicin (Doxil) could augment abscopal responses compared with RT/αPD-1 and Doxil/αPD-1. We also investigated whether the enhanced abscopal responses depended on the mitochondrial DNA (mtDNA)/cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING)/IFN-I pathway. We used Doxil in combination with RT and αPD-1 in two tumor models (B16-CD133 melanoma and MC38 colon carcinoma) with mice bearing two tumors, only one of which was irradiated. Mechanistic studies on the role of the mtDNA/cGAS/STING/IFN-I axis were performed using inhibitors and knockout cells in vitro as well as in mice. Addition of a single low dose of Doxil to RT and αPD-1 strongly enhanced the RT/αPD-1-induced abscopal effect in both models. Complete cures of non-irradiated tumors were mainly observed in triple-treated mice. Triple therapy induced more cross-presenting dendritic cells (DCs) and more tumor-specific CD8 These data show that single low-dose Doxil can substantially enhance the RT/αPD-1-induced abscopal effect, with a strong increase in cross-presenting DCs and CD8
Sections du résumé
BACKGROUND
Localized radiotherapy (RT) can cause a T cell-mediated abscopal effect on non-irradiated tumor lesions, especially in combination with immune checkpoint blockade. However, this effect is still clinically rare and improvements are highly desirable. We investigated whether triple combination with a low dose of clinically approved liposomal doxorubicin (Doxil) could augment abscopal responses compared with RT/αPD-1 and Doxil/αPD-1. We also investigated whether the enhanced abscopal responses depended on the mitochondrial DNA (mtDNA)/cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING)/IFN-I pathway.
MATERIALS/METHODS
We used Doxil in combination with RT and αPD-1 in two tumor models (B16-CD133 melanoma and MC38 colon carcinoma) with mice bearing two tumors, only one of which was irradiated. Mechanistic studies on the role of the mtDNA/cGAS/STING/IFN-I axis were performed using inhibitors and knockout cells in vitro as well as in mice.
RESULTS
Addition of a single low dose of Doxil to RT and αPD-1 strongly enhanced the RT/αPD-1-induced abscopal effect in both models. Complete cures of non-irradiated tumors were mainly observed in triple-treated mice. Triple therapy induced more cross-presenting dendritic cells (DCs) and more tumor-specific CD8
CONCLUSIONS
These data show that single low-dose Doxil can substantially enhance the RT/αPD-1-induced abscopal effect, with a strong increase in cross-presenting DCs and CD8
Identifiants
pubmed: 37640480
pii: jitc-2022-006235
doi: 10.1136/jitc-2022-006235
pmc: PMC10462948
pii:
doi:
Substances chimiques
DNA, Mitochondrial
0
liposomal doxorubicin
0
Doxorubicin
80168379AG
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Nature. 2015 Apr 23;520(7548):553-7
pubmed: 25642965
Clin Cancer Res. 2023 Feb 1;29(3):667-683
pubmed: 36449659
Trends Cancer. 2022 Jan;8(1):9-20
pubmed: 34740553
J Exp Med. 2011 Sep 26;208(10):2005-16
pubmed: 21930765
Cell Rep. 2019 Oct 29;29(5):1236-1248.e7
pubmed: 31665636
Nat Commun. 2017 Jun 09;8:15618
pubmed: 28598415
Sci Adv. 2021 Oct 08;7(41):eabf6290
pubmed: 34613770
Nat Immunol. 2020 Nov;21(11):1470
pubmed: 32939095
Immunol Rev. 2017 Nov;280(1):249-279
pubmed: 29027221
Sci Transl Med. 2021 Jul 14;13(602):
pubmed: 34261797
Nat Rev Clin Oncol. 2020 Dec;17(12):725-741
pubmed: 32760014
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
Nat Rev Immunol. 2008 Jan;8(1):59-73
pubmed: 18097448
Cancer Cell. 2018 Sep 10;34(3):361-378
pubmed: 30216189
Nat Med. 2014 Nov;20(11):1301-9
pubmed: 25344738
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32209603
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cell Death Differ. 2014 Jan;21(1):69-78
pubmed: 23811849
Nanomedicine (Lond). 2016 Sep;11(18):2431-41
pubmed: 27558906
Oncoimmunology. 2013 Jun 1;2(6):e24568
pubmed: 23894718
J Exp Med. 2011 Sep 26;208(10):1989-2003
pubmed: 21930769
Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):63-73
pubmed: 29534901
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33106386
Immunity. 2019 Dec 17;51(6):1043-1058.e4
pubmed: 31810882
Nat Med. 2019 Jun;25(6):920-928
pubmed: 31086347
Nat Cancer. 2020 Feb;1(2):184-196
pubmed: 33768207
Immunity. 2014 Nov 20;41(5):843-52
pubmed: 25517616
Nat Rev Cancer. 2018 May;18(5):313-322
pubmed: 29449659
J Control Release. 2018 Jan 10;269:364-373
pubmed: 29146246
Cancer Discov. 2021 Jun;11(6):1353-1367
pubmed: 33712487
Cell Death Dis. 2020 Nov 26;11(11):1013
pubmed: 33243969
Bio Protoc. 2016 Jun 20;6(12):
pubmed: 31106234
Cancer Res. 2007 May 15;67(10):5009-16
pubmed: 17510433
Int J Nanomedicine. 2020 Jul 27;15:5279-5288
pubmed: 32801691
Nat Rev Immunol. 2015 Jul;15(7):405-14
pubmed: 26027717
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Nature. 2017 Aug 24;548(7668):466-470
pubmed: 28759889
J Natl Cancer Inst. 1986 Aug;77(2):459-69
pubmed: 3461207
Clin Cancer Res. 2019 Dec 1;25(23):7243-7255
pubmed: 31506388
Immunity. 2013 Apr 18;38(4):729-41
pubmed: 23562161
Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):212-224
pubmed: 32417411
Science. 1989 Oct 27;246(4929):500-3
pubmed: 2814477
Somat Cell Mol Genet. 1997 Jul;23(4):287-90
pubmed: 9542530
mBio. 2017 Apr 4;8(2):
pubmed: 28377530
Nat Commun. 2015 Jun 25;6:7458
pubmed: 26109379
Neoplasia. 2015 Aug;17(8):661-70
pubmed: 26408258
J Exp Med. 2005 Dec 19;202(12):1691-701
pubmed: 16365148
J Immunother Cancer. 2021 Apr;9(4):
pubmed: 33827904
Oncoimmunology. 2017 Oct 4;6(12):e1386829
pubmed: 29209573
J Clin Invest. 2021 Feb 1;131(3):
pubmed: 33290271
Cancer Res. 2016 Aug 15;76(16):4673-83
pubmed: 27302161
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
J Nanobiotechnology. 2021 Apr 13;19(1):102
pubmed: 33849551
Nat Metab. 2019 Dec;1(12):1209-1218
pubmed: 32395698
Nat Immunol. 2020 Oct;21(10):1160-1171
pubmed: 32747819
J Clin Invest. 2019 Aug 13;129(11):4850-4862
pubmed: 31408442